Bob van Gemen
Director/Miembro de la Junta en Genome Diagnostics BV .
Perfil
Bob van Gemen is a Non-Executive Director at Genome Diagnostics BV since 2021.
He was previously the Chief Executive Officer at PrimaGen Holding BV and ViroClinics Biosciences BV from 2011 to 2020.
He also worked as a Principal at Akzo Nobel NV.
Dr. van Gemen holds a doctorate degree from the University of Leiden.
Cargos activos de Bob van Gemen
| Empresas | Cargo | Inicio |
|---|---|---|
Genome Diagnostics BV
 Genome Diagnostics BV Medical SpecialtiesHealth Technology Genome Diagnostics BV develops and markets vitro diagnostic tests and services, analysis software & education. Its products include NGSengine, SBTexcellerator, AlleleSEQR and SBTengine. The company was founded by Martijn Rozemuller, Wietse Mulder, Oscar Schoots, and Raoul Linschoten in March 2005 and is headquartered in Utrecht, the Netherlands. | Director/Miembro de la Junta | 01/08/2021 |
Antiguos cargos conocidos de Bob van Gemen.
| Empresas | Cargo | Fin |
|---|---|---|
ViroClinics Biosciences BV
 ViroClinics Biosciences BV Pharmaceuticals: MajorHealth Technology ViroClinics Biosciences BV engages in the provision of diagnostic and clinical trial solutions. It offers research and development, preclinical, clinical trial operation, diagnostic testing, virus discovery, and quality assurance services. The company was founded by Albert Osterhaus in 2001 and is headquartered in Rotterdam, the Netherlands. | Director Ejecutivo | 01/08/2020 |
| AKZO NOBEL N.V. | Corporate Officer/Principal | - |
PrimaGen Holding BV
 PrimaGen Holding BV Miscellaneous Commercial ServicesCommercial Services PrimaGen Holding BV designs and develops molecular diagnostic tests. The firm conducts tests in the fields of mitochondrial toxicity, drug development toxicology screening, HIV monitoring, DFS paper technology, oncology and virus discovery. It also develops in monitoring toxic side effects of antiviral medication and for diagnosing and monitoring certain forms of cancer. The company was founded in November 2001 and is headquartered in Amsterdam, the Netherlands. | Director Ejecutivo | - |
Formación de Bob van Gemen.
| University of Leiden | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| AKZO NOBEL N.V. | Process Industries |
| Empresas privadas | 3 |
|---|---|
PrimaGen Holding BV
PrimaGen Holding BV Miscellaneous Commercial ServicesCommercial Services PrimaGen Holding BV designs and develops molecular diagnostic tests. The firm conducts tests in the fields of mitochondrial toxicity, drug development toxicology screening, HIV monitoring, DFS paper technology, oncology and virus discovery. It also develops in monitoring toxic side effects of antiviral medication and for diagnosing and monitoring certain forms of cancer. The company was founded in November 2001 and is headquartered in Amsterdam, the Netherlands. | Commercial Services |
ViroClinics Biosciences BV
ViroClinics Biosciences BV Pharmaceuticals: MajorHealth Technology ViroClinics Biosciences BV engages in the provision of diagnostic and clinical trial solutions. It offers research and development, preclinical, clinical trial operation, diagnostic testing, virus discovery, and quality assurance services. The company was founded by Albert Osterhaus in 2001 and is headquartered in Rotterdam, the Netherlands. | Health Technology |
Genome Diagnostics BV
Genome Diagnostics BV Medical SpecialtiesHealth Technology Genome Diagnostics BV develops and markets vitro diagnostic tests and services, analysis software & education. Its products include NGSengine, SBTexcellerator, AlleleSEQR and SBTengine. The company was founded by Martijn Rozemuller, Wietse Mulder, Oscar Schoots, and Raoul Linschoten in March 2005 and is headquartered in Utrecht, the Netherlands. | Health Technology |
- Bolsa de valores
- Insiders
- Bob van Gemen
